RJA
TXG icon

Raymond James & Associates’s 10x Genomics TXG Stock Holding History

Raymond James & Associates’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,270
Closed -$407K – 4041
2023
Q4 		$407K Sell
7,270
-873
-11% -$38K ﹤0.01% 3078
2023
Q3 		$336K Sell
8,143
-2,760
-25% -$144K ﹤0.01% 3136
2023
Q2 		$609K Buy
+10,903
New +$590K ﹤0.01% 2804
2023
Q1 		– Sell
-35,123
Closed -$1.28M – 4079
2022
Q4 		$1.28M Sell
35,123
-10,531
-23% -$344K ﹤0.01% 2288
2022
Q3 		$1.3M Sell
45,654
-5,151
-10% -$196K ﹤0.01% 2240
2022
Q2 		$2.3M Sell
50,805
-2,204
-4% -$114K ﹤0.01% 1906
2022
Q1 		$4.03M Buy
53,009
+8,570
+19% +$750K ﹤0.01% 1668
2021
Q4 		$6.62M Buy
44,439
+37,999
+590% +$5.82M 0.01% 1353
2021
Q3 		$938K Sell
6,440
-2,874
-31% -$493K ﹤0.01% 2620
2021
Q2 		$1.82M Sell
9,314
-12,593
-57% -$2.28M ﹤0.01% 2163
2021
Q1 		$3.96M Sell
21,907
-2,129
-9% -$368K ﹤0.01% 1577
2020
Q4 		$3.4M Buy
24,036
+18,254
+316% +$2.65M ﹤0.01% 1558
2020
Q3 		$721K Buy
5,782
+3,284
+131% +$345K ﹤0.01% 2382
2020
Q2 		$223K Sell
2,498
-11,534
-82% -$898K ﹤0.01% 3069
2020
Q1 		$874K Buy
+14,032
New +$1.1M ﹤0.01% 2070

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Raymond James & Associates's TXG Position: Q1 2024 in Review

Raymond James & Associates sold out of 10x Genomics (TXG) in Q1 2024, closing a stake of 7,270 shares — an estimated $407K sold.

Raymond James & Associates first reported a position in TXG in Q1 2020 and held it in 15 quarters. The position peaked at $6.62M in Q4 2021. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

  • Raymond James & Associates reported no remaining 10x Genomics position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 7,270 10x Genomics shares in Q1 2024, an estimated $407K.
  • Raymond James & Associates first reported a position in 10x Genomics in Q1 2020 and held it in 15 quarters.
  • Raymond James & Associates's 10x Genomics position peaked at $6.62M in Q4 2021.
  • 290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.